NasdaqCM - Nasdaq Real Time Price USD
Benitec Biopharma Inc. (BNTC)
16.00
+0.83
+(5.47%)
At close: June 6 at 4:00:01 PM EDT
16.70
+0.70
+(4.37%)
After hours: June 6 at 6:56:59 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman & CEO | 665.89k | -- | 1976 |
| Ms. Megan Joan Boston B.Com., C.A. | CFO & Director | 362.58k | -- | 1973 |
| Ms. Sophie Mukadam | Chief Operating Officer | -- | -- | -- |
| Dr. Michael Graham | Head of Discovery & Founding Scientist | 125.53k | -- | -- |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing | -- | -- | -- |
Benitec Biopharma Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16
Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Corporate Governance
Benitec Biopharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 14, 2025 at 11:00 AM UTC
Benitec Biopharma Inc. Earnings Date
Recent Events
Related Tickers
AKTX Akari Therapeutics, Plc
1.2320
-3.90%
SOFTX.OL SoftOx Solutions AS
0.0810
+11.26%
IMTX Immatics N.V.
5.97
+3.29%
ENTX Entera Bio Ltd.
2.0700
+2.99%
PTCT PTC Therapeutics, Inc.
52.13
+0.77%
XBIO Xenetic Biosciences, Inc.
2.9565
-6.28%
PHVS Pharvaris N.V.
16.78
+4.55%
ACLX Arcellx, Inc.
68.10
+2.79%
IMVT Immunovant, Inc.
16.77
+4.68%
CRNX Crinetics Pharmaceuticals, Inc.
33.01
+2.13%